DAVID GEORGE STANDAERT, MD PHD
Medical Practice at 19 St, Birmingham, AL
License number
Alabama 27659
Category
Medical Practice
Type
Neurological Surgery
Address
Address
619 19Th St SOUTH, Birmingham, AL 35255
Phone
(205) 934-6600
(205) 731-9050
(205) 731-9050
Personal information
See more information about DAVID GEORGE STANDAERT at radaris.comName
Address
Phone
4234 Marden Way, Vestavia, AL 35242
2000 Stonegate Dr, Birmingham, AL 35242
4234 Marden Dr, Vestavia, AL 35242
Professional information
Dr. David G Standaert, Birmingham AL - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
Birmingham
619 19Th St S, Birmingham 35233
(205) 934-9999 (Phone), (205) 975-9694 (Fax)
UAB Hosp Kirkland Clin Neurlg
619 19Th St S, Birmingham 35249
(205) 801-8950 (Phone)
619 19Th St S, Birmingham 35233
(205) 934-9999 (Phone), (205) 975-9694 (Fax)
UAB Hosp Kirkland Clin Neurlg
619 19Th St S, Birmingham 35249
(205) 801-8950 (Phone)
Certifications:
Neurology, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Birmingham
619 19Th St S, Birmingham 35233
UAB Hosp Kirkland Clin Neurlg
619 19Th St S, Birmingham 35249
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
619 19Th St S, Birmingham 35233
UAB Hosp Kirkland Clin Neurlg
619 19Th St S, Birmingham 35249
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1988
Washington Center / School of Medicine
Graduated: 1988
Use Of 14-3-3- Proteins In Treatment And Prevention Of Neurodegeneration
US Patent:
2009018, Jul 23, 2009
Filed:
Nov 7, 2008
Appl. No.:
12/267337
Inventors:
Talene Alene Yacoubian - Birmingham AL, US
David G. Standaert - Birmingham AL, US
David G. Standaert - Birmingham AL, US
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity.
Cathepsin-D Neuroprotection
US Patent:
2011006, Mar 17, 2011
Filed:
Jul 2, 2008
Appl. No.:
12/667832
Inventors:
Jianhua Zhang - Birmingham AL, US
Guy Caldwell - Northport AL, US
Kevin Roth - Birmingham AL, US
David Standaert - Birmingham AL, US
Kim Cladwell - Northport AL, US
Shusei Hamamichi - Tuscaloosa AL, US
Guy Caldwell - Northport AL, US
Kevin Roth - Birmingham AL, US
David Standaert - Birmingham AL, US
Kim Cladwell - Northport AL, US
Shusei Hamamichi - Tuscaloosa AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
THE UNIVERSITY OF ALABAMA - Tuscaloosa AL
THE UNIVERSITY OF ALABAMA - Tuscaloosa AL
International Classification:
A61K 39/395, C12Q 1/37, A61K 38/02, A61P 25/28, A61P 25/16, A61K 31/7088, C12Q 1/68, A61K 38/48
US Classification:
4241301, 435 23, 514 178, 514 44 R, 435 6, 424 9466, 514 177
Abstract:
Provided herein are methods and compositions for promoting neuroprotection in a subject and for treating a neural disorder associated with protein aggregation comprising administering to the subject an agent that increases expression or activity of cathepsin-D. Also provided are methods of screening for agents that increase expression or activity of cathepsin-D and methods of screening for neuroprotective agents.
Use Of 14-3-3-Proteins In Treatment And Prevention Of Neurodegeneration
US Patent:
2011018, Jul 28, 2011
Filed:
Mar 29, 2011
Appl. No.:
13/075062
Inventors:
Talene Alene Yacoubian - Birmingham AL, US
David G. Standaert - Birmingham AL, US
David G. Standaert - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
C12Q 1/68, G01N 33/53, C12Q 1/26
US Classification:
435 612, 435 71, 435 25, 435 61
Abstract:
The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity.